Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press81010.17650/1994-4098-2021-17-1-20-26MAMMOLOGY. REVIEWSМАММОЛОГИЯ. ОБЗОРНЫЕ СТАТЬИ[18F]-Fluoroestradiol PET/CT: a modern look at nuclear medicine applicationsПЭТ/КТ с 18F-фторэстрадиолом: современный взгляд на применение в ядерной медицинеhttps://orcid.org/0000-0002-2963-4176ParnasA.   V.ПарнасА. В.
Russian Federation

Aleksandr Vadimovich Parnas 

2/1 Barrikadnaya St., Moscow 125993

Александр Вадимович Парнас  

125993 Москва, ул. Баррикадная, 2/1, стр. 1

alexandrparnas@gmail.comhttps://orcid.org/0000-0003-1632-351XProninA.   I.ПронинА. И.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское шоссе, 24

https://orcid.org/0000-0002-5375-2498IlyakovV.  S. ИльяковВ. С.
Russian Federation

2/1 Barrikadnaya St., Moscow 125993

125993 Москва, ул. Баррикадная, 2/1, стр. 1

https://orcid.org/0000-0003-0770-3406MeshcheryakovaN.   A.МещеряковаН. А.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское шоссе, 24

https://orcid.org/0000-0002-4376-3978KamolovaZ.  Kh. КамоловаЗ. Х.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское шоссе, 24

https://orcid.org/0000-0001-7460-3267MikhaylovA.  I. МихайловА. И.
Russian Federation

5 2 nd Botkinskiy Proezd, Moscow 125284

125284 Москва, 2-й Боткинский проезд, 5

Russian Medical Academy of Postgraduate Education, Ministry of Health of RussiaФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииN.N. Blokhin Russian Cancer Research Center, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава РоссииS.P. Botkin City Clinical Hospital of the Moscow Healthcare DepartmentГБУЗ г. Москвы «Городская клиническая больница им. С.П. Боткина Департамента здравоохранения г. Москвы»1606202117120261606202116062021https://ojrs.abvpress.ru/ojrs/article/view/810

Breast cancer is one of the most commonly diagnosed cancers and the leading cause of cancer mortality among women. Approximately 70–80 % of breast cancers are estrogen (ER) and/or progesterone receptor-positive, thus making endocrine therapy an important stage of treatment. Receptor expression in breast cancer cells is usually assessed by tissue immunohistochemistry. The method of positron emission tomography, combined with computed tomography (PET/CT), makes it possible to evaluate not only anatomical and structural, but also metabolic changes in tumor tissue. 18F-Fluoroestradiol (18F-FES) is a radiopharmaceutical drug, an estradiol analogue, which is used in the diagnostics of ER-expressing tumors and is utilized for detection and quantification of ER expression in vivo. Various studies show that 18F-FES accumulation indicates presence of ER-positive tumor tissue, which, in most cases, is confirmed by tissue immunohistochemistry. Although current guidelines recommend 18F-fluorodeoxyglucose PET/CT when routine examinations demonstrate ambiguous results, 18F-FES PET/CT can be the preferable imaging modality in the diagnostics of ER-positive breast cancer. It should be noted, that PET/CT with 18F-FES can also be effective for evaluation of tumors with a high level of ER expression, like ovarian cancer.

Рак молочной железы – одно из наиболее часто диагностируемых онкологических заболеваний и ведущая причина смерти от рака у женщин. Примерно 70–80 % случаев рака молочной железы являются положительными по рецепторам эстрогена (РЭ) и/или прогестерона, что делает эндокринную терапию важным этапом лечения. Экспрессия РЭ при раке молочной железы обычно оценивается путем иммуногистохимического исследования ткани. Метод позитронно-эмиссионной томографии, совмещенной с компьютерной томографией (ПЭТ/КТ), позволяет оценить не только анатомические и структурные, но и метаболические изменения в опухолевой ткани. 18F-фторэстрадиол (18F-ФЭС) – радиофармацевтический лекарственный препарат, аналог эстрадиола, который используется в диагностике опухолей, экспрессирующих РЭ. Применение 18F-ФЭС является неинвазивным методом молекулярной визуализации для определения и количественной оценки экспрессии РЭ in vivo. Различные исследования показывают, что накопление 18F-ФЭС указывает на РЭ-положительную опухолевую ткань, что в большинстве случаев подтверждается при иммуногистохимическом исследовании биоптата. Хотя современные руководства рекомендуют выполнять ПЭТ/КТ с 18F-фтордезоксиглюкозой, когда рутинные методы обследования не дают однозначного ответа, ПЭТ/КТ с 18F-ФЭС у пациентов с РЭположительным раком молочной железы может быть методом выбора. Следует отметить, что ПЭТ/КТ с 18F-ФЭС может помочь в диагностике опухолей с высоким уровнем экспрессии РЭ, в частности рака яичников.

PET/CT18F-FDG18F-FESestrogen receptorsbreast cancerПЭТ/КТ18F-ФДГ18F-ФЭСрецепторы эстрогенарак молочной железы1. Bray F., Ferlay J., Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394–424. DOI: 10.3322/caac.21492.Bray F., Ferlay J., Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394–424. DOI: 10.3322/caac.21492.2. State of cancer care for the population of Russia in 2019. Eds.: A.D. Kaprin, V.V. Starinsky, A.O. Shakhzadova. Moscow: P. Hertsen Moscow Oncology Research Institute – branch of National Medical Radioligy Research Center, 2020. 239 p.State of cancer care for the population of Russia in 2019. Eds.: A.D. Kaprin, V.V. Starinsky, A.O. Shakhzadova. Moscow: P. Hertsen Moscow Oncology Research Institute – branch of National Medical Radioligy Research Center, 2020. 239 p.3. Vikhrova N.B., Odzharova A.A., Dolgushin M.B., Nevzorov D.I. 18Ffluoroestradiol PET/CT in differential diagnosis of lung lesions in breast cancer patients: case reports. Sib J Oncol 2018;17(5):111–8. DOI: 0.21294/1814-4861-2018-17-5-111-118.Vikhrova N.B., Odzharova A.A., Dolgushin M.B., Nevzorov D.I. 18Ffluoroestradiol PET/CT in differential diagnosis of lung lesions in breast cancer patients: case reports. Sib J Oncol 2018;17(5):111–8. DOI: 0.21294/1814-4861-2018-17-5-111-118.4. Avril S., Muzic R.F., Plecha Jr.D. et al. 18F-FDG PET/CT for monitoring of treatment response in breast cancer. J Nucl Med 2016;57(Suppl 1):34S– 39S. DOI: 10.2967/jnumed.115.157875.Avril S., Muzic R.F., Plecha Jr.D. et al. 18F-FDG PET/CT for monitoring of treatment response in breast cancer. J Nucl Med 2016;57(Suppl 1):34S– 39S. DOI: 10.2967/jnumed.115.157875.5. Venema C.M., Apollonio G., Hospers G.A. et al. Recommendations and technical aspects of 16α-[18F]Fluoro- 17β-Estradiol PET to image the estrogen receptor in vivo: The Groningen experience. Clin Nucl Med 2016;41(11):844–51. DOI: 10.1097/RLU.0000000000001347.Venema C.M., Apollonio G., Hospers G.A. et al. Recommendations and technical aspects of 16α-[18F]Fluoro- 17β-Estradiol PET to image the estrogen receptor in vivo: The Groningen experience. Clin Nucl Med 2016;41(11):844–51. DOI: 10.1097/RLU.0000000000001347.6. Mankoff D.A., Tewson T.J., Eary J.F. Analysis of blood clearance and labeled metabolites for the estrogen receptor tracer [F18]-16-alpha-fluoroestradiol. Nucl Med Biol 1997;24:341–8.Mankoff D.A., Tewson T.J., Eary J.F. Analysis of blood clearance and labeled metabolites for the estrogen receptor tracer [F18]-16-alpha-fluoroestradiol. Nucl Med Biol 1997;24:341–8.7. Liu C., Gong C., Liu S. et al. 18F-FES PET/CT influences the staging and management of patients with newly diagnosed estrogen receptor-positive breast cancer: A retrospective comparative study with 18F-FDG PET/CT. Oncologist 2019;24(12):e1277–85. DOI: 10.1634/theoncologist.2019-0096.Liu C., Gong C., Liu S. et al. 18F-FES PET/CT influences the staging and management of patients with newly diagnosed estrogen receptor-positive breast cancer: A retrospective comparative study with 18F-FDG PET/CT. Oncologist 2019;24(12):e1277–85. DOI: 10.1634/theoncologist.2019-0096.8. Seenu V., Sharma A., Kumar R. et al. Evaluation of estrogen expression of breast cancer using 18F-FES PET/CT – A novel technique. World J Nucl Med 2020;19:233–9.Seenu V., Sharma A., Kumar R. et al. Evaluation of estrogen expression of breast cancer using 18F-FES PET/CT – A novel technique. World J Nucl Med 2020;19:233–9.9. Peterson L., Manohar P., Wu V. et al. 18F-Fluoroestradiol (FES) and 18F-Fluorodeoxyglucose (FDG) PET imaging in male breast cancer. J Nucl Med 2018;59(Suppl 1):54.Peterson L., Manohar P., Wu V. et al. 18F-Fluoroestradiol (FES) and 18F-Fluorodeoxyglucose (FDG) PET imaging in male breast cancer. J Nucl Med 2018;59(Suppl 1):54.10. Tewson T.J., Mankoff D.A., Peterson L.M. et al. Interactions of 16alpha-[18F]-fluoroestradiol (FES) with sex steroid binding protein (SBP). Nucl Med Biol 1999;26:905–13.Tewson T.J., Mankoff D.A., Peterson L.M. et al. Interactions of 16alpha-[18F]-fluoroestradiol (FES) with sex steroid binding protein (SBP). Nucl Med Biol 1999;26:905–13.11. Linden H.M., Kurland B.F., Peterson L.M. et al. Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromataseinhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer. Clin Cancer Res 2011;17:4799–805.Linden H.M., Kurland B.F., Peterson L.M. et al. Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromataseinhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer. Clin Cancer Res 2011;17:4799–805.12. Nienhuis H.H., van Kruchten M., Glaudemans A.W.J.M. et al. FES PET/CT analysis to evaluate the impact of localization of breast cancer metastases on ER expression. J Clin Oncol 2015;33:527.Nienhuis H.H., van Kruchten M., Glaudemans A.W.J.M. et al. FES PET/CT analysis to evaluate the impact of localization of breast cancer metastases on ER expression. J Clin Oncol 2015;33:527.13. Van Kruchten M., Hospers G.A., Glaudemans A.W. et al. Positron emission tomography imaging of oestrogen receptor-expression in endometrial stromal sarcoma supports oestrogen receptor-targeted therapy: case report and review of the literature. Eur J Cancer 2013;49:3850–5.Van Kruchten M., Hospers G.A., Glaudemans A.W. et al. Positron emission tomography imaging of oestrogen receptor-expression in endometrial stromal sarcoma supports oestrogen receptor-targeted therapy: case report and review of the literature. Eur J Cancer 2013;49:3850–5.14. Yi J.H., Do I.G., Jang J. et al. Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer. Sci Rep 2014;4:7592.Yi J.H., Do I.G., Jang J. et al. Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer. Sci Rep 2014;4:7592.15. Di Zazzo E., Galasso G., Giovannelli P. et al. Prostate cancer stem cells: the role of androgen and estrogen receptors. Oncotarget 2016;7:193–208.Di Zazzo E., Galasso G., Giovannelli P. et al. Prostate cancer stem cells: the role of androgen and estrogen receptors. Oncotarget 2016;7:193–208.16. Moresco R.M., Scheithauer B.W., Lucignani G. et al. Oestrogen receptors in meningiomas: a correlative PET and immunohistochemical study. Nucl Med Commun 1997;18:606–15.Moresco R.M., Scheithauer B.W., Lucignani G. et al. Oestrogen receptors in meningiomas: a correlative PET and immunohistochemical study. Nucl Med Commun 1997;18:606–15.17. Kumar M., Salem K., Michel C. et al. 18F-Fluoroestradiol PET imaging of activating estrogen receptor-α mutations in breast cancer. J Nucl Med 2019;60(9):1247–52. DOI: 10.2967/jnumed.118.224667.Kumar M., Salem K., Michel C. et al. 18F-Fluoroestradiol PET imaging of activating estrogen receptor-α mutations in breast cancer. J Nucl Med 2019;60(9):1247–52. DOI: 10.2967/jnumed.118.224667.18. Riedl C.C., Pinker K., Ulaner G.A. et al. Comparison of FDG-PET/CТ and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer. Eur J Nucl Med Mol Imaging 2017;44:1428–37. DOI: 10.1007/s00259-017-3703-7.Riedl C.C., Pinker K., Ulaner G.A. et al. Comparison of FDG-PET/CТ and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer. Eur J Nucl Med Mol Imaging 2017;44:1428–37. DOI: 10.1007/s00259-017-3703-7.19. Kitajima K., Miyoshi Y. Present and future role of FDG-PET/CT imaging in the management of breast cancer. Jpn J Radiol 2016;34:167–80. DOI: 10.1007/s11604-015-0516-0.Kitajima K., Miyoshi Y. Present and future role of FDG-PET/CT imaging in the management of breast cancer. Jpn J Radiol 2016;34:167–80. DOI: 10.1007/s11604-015-0516-0.20. Segaert I., Mottaghy F., Ceyssens S. et al. Additional value of PET-CT in staging of clinical stage IIB and III breast cancer. Breast J 2010;16:617–24. DOI: 10.1111/j.1524-4741.2010.00987.x.Segaert I., Mottaghy F., Ceyssens S. et al. Additional value of PET-CT in staging of clinical stage IIB and III breast cancer. Breast J 2010;16:617–24. DOI: 10.1111/j.1524-4741.2010.00987.x.21. Nakai T., Okuyama C., Kubota T. et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging 2005;32:1253–8.Nakai T., Okuyama C., Kubota T. et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging 2005;32:1253–8.22. Sun Z., Yi Y.L., Liu Y. et al. Comparison of whole-body PET/PET-CT and conventional imaging procedures for distant metastasis staging in patients with breast cancer: A meta-analysis. Eur J Gynaecol Oncol 2015;36:672–6.Sun Z., Yi Y.L., Liu Y. et al. Comparison of whole-body PET/PET-CT and conventional imaging procedures for distant metastasis staging in patients with breast cancer: A meta-analysis. Eur J Gynaecol Oncol 2015;36:672–6.23. Ugurluer G., Kibar M., Yavuz S. et al. False positive 18F-FDG uptake in mediastinal lymph nodes detected with positron emission tomography in breast cancer: A case report. Case Rep Med 2013;2013:459753.Ugurluer G., Kibar M., Yavuz S. et al. False positive 18F-FDG uptake in mediastinal lymph nodes detected with positron emission tomography in breast cancer: A case report. Case Rep Med 2013;2013:459753.24. Ataergin S., Arslan N., Ozet A. et al. Abnormal 18F-FDG uptake detected with positron emission tomography in a patient with breast cancer: A case of sarcoidosis and review of the literature. Case Rep Med 2009;2009:785047.Ataergin S., Arslan N., Ozet A. et al. Abnormal 18F-FDG uptake detected with positron emission tomography in a patient with breast cancer: A case of sarcoidosis and review of the literature. Case Rep Med 2009;2009:785047.25. Rugo H.S., Rumble R.B., Macrae E. et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology guideline. J Clin Oncol 2016;34:3069–103.Rugo H.S., Rumble R.B., Macrae E. et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology guideline. J Clin Oncol 2016;34:3069–103.26. Porter A.J., Evans E.B., Foxcroft L.M. et al. Mammographic and ultrasound features of invasive lobular carcinoma of the breast. J Med Imaging Radiat Oncol 2014;58:1–10.Porter A.J., Evans E.B., Foxcroft L.M. et al. Mammographic and ultrasound features of invasive lobular carcinoma of the breast. J Med Imaging Radiat Oncol 2014;58:1–10.27. Groheux D., Majdoub M., Tixier F. et al. Do clinical, histological or immunohistochemical primary tumour characteristics translate into different [18]FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer? Eur J Nucl Med Mol Imaging 2015;42:1682–91.Groheux D., Majdoub M., Tixier F. et al. Do clinical, histological or immunohistochemical primary tumour characteristics translate into different [18]FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer? Eur J Nucl Med Mol Imaging 2015;42:1682–91.28. Van Kruchten M., de Vries E.G., Brown M. et al. PET imaging of oestrogen receptors in patients with breast cancer. Lancet Oncol 2013;14:e465–75.Van Kruchten M., de Vries E.G., Brown M. et al. PET imaging of oestrogen receptors in patients with breast cancer. Lancet Oncol 2013;14:e465–75.29. Chae S.Y., Son H.J., Lee D.Y. et al. Comparison of diagnostic sensitivity of [18F]fluoroestradiol and [18F]fluorodeoxyglucose positron emission tomography/ computed tomography for breast cancer recurrence in patients with a history of estrogen receptor-positive primary breast cancer. EJNMMI Res 2020;10:54. DOI: 10.1186/s13550-020-00643-z.Chae S.Y., Son H.J., Lee D.Y. et al. Comparison of diagnostic sensitivity of [18F]fluoroestradiol and [18F]fluorodeoxyglucose positron emission tomography/ computed tomography for breast cancer recurrence in patients with a history of estrogen receptor-positive primary breast cancer. EJNMMI Res 2020;10:54. DOI: 10.1186/s13550-020-00643-z.30. Liao G.J., Clark A.S., Schubert E.K. et al. 18F-fluoroestradiol PET: Current status and potential future clinical applications. J Nucl Med 2016;57:1269–75.Liao G.J., Clark A.S., Schubert E.K. et al. 18F-fluoroestradiol PET: Current status and potential future clinical applications. J Nucl Med 2016;57:1269–75.31. Evangelista L., Vittoria Dieci M., Guarneri V., Franco Conte P. 18F-Fluoroestradiol positron emission tomography in breast cancer patients: Systematic review of the literature & meta-analysis. Curr Radiopharmaceuticals 2016;9:244. DOI: 10.2174/1874471009666161019144950.Evangelista L., Vittoria Dieci M., Guarneri V., Franco Conte P. 18F-Fluoroestradiol positron emission tomography in breast cancer patients: Systematic review of the literature & meta-analysis. Curr Radiopharmaceuticals 2016;9:244. DOI: 10.2174/1874471009666161019144950.32. Chae S.Y., Ahn S.H., Kim S.B. et al. Diagnostic accuracy and safety of 16α-[18F]fluoro-17β-oestradiol PETCT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: A prospective cohort study. Lancet Oncol 2019;20(4):546–55. DOI: 10.1016/S1470-2045(18)30936-7.Chae S.Y., Ahn S.H., Kim S.B. et al. Diagnostic accuracy and safety of 16α-[18F]fluoro-17β-oestradiol PETCT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: A prospective cohort study. Lancet Oncol 2019;20(4):546–55. DOI: 10.1016/S1470-2045(18)30936-7.33. Seimbille Y., Rousseau J., Benard F. et al. 18F-labeled difluoroestradiols: preparation and preclinical evaluation as estrogen receptor-binding radiopharmaceuticals. Steroids 2002;67:765–75.Seimbille Y., Rousseau J., Benard F. et al. 18F-labeled difluoroestradiols: preparation and preclinical evaluation as estrogen receptor-binding radiopharmaceuticals. Steroids 2002;67:765–75.34. Van Kruchten M., de Vries E.F., Arts H.J. et al. Assessment of estrogen receptor expression in epithelial ovarian cancer patients using 16α-[18F]fluoro-17β-estradiol PET/CT. J Nucl Med 2015;56:50–5.Van Kruchten M., de Vries E.F., Arts H.J. et al. Assessment of estrogen receptor expression in epithelial ovarian cancer patients using 16α-[18F]fluoro-17β-estradiol PET/CT. J Nucl Med 2015;56:50–5.35. Couse J.F., Lindzey J., Grandien K. et al. Tissue distribution and quantitative analysis of estrogen receptor-α (ERα) and estrogen receptor-β (ERβ) messenger ribonucleic acid in the wild-type and ERα-knockout mouse. Endocrinology 1997;138:4613–21.Couse J.F., Lindzey J., Grandien K. et al. Tissue distribution and quantitative analysis of estrogen receptor-α (ERα) and estrogen receptor-β (ERβ) messenger ribonucleic acid in the wild-type and ERα-knockout mouse. Endocrinology 1997;138:4613–21.36. Zhao Z., Yoshida Y., Kurokawa T. et al. 18F-FES and 18F-FDG PET for differential diagnosis and quantitative evaluation of mesenchymal uterine tumors: correlation with immunohistochemical analysis. J Nucl Med 2013;54:499–506.Zhao Z., Yoshida Y., Kurokawa T. et al. 18F-FES and 18F-FDG PET for differential diagnosis and quantitative evaluation of mesenchymal uterine tumors: correlation with immunohistochemical analysis. J Nucl Med 2013;54:499–506.37. Tsuchida T., Okazawa H., Mori T. et al. In vivo imaging of estrogen receptor concentration in the endometrium and myometrium using FES PET – influence of menstrual cycle and endogenous estrogen level. Nucl Med Biol 2007;34:205–10.Tsuchida T., Okazawa H., Mori T. et al. In vivo imaging of estrogen receptor concentration in the endometrium and myometrium using FES PET – influence of menstrual cycle and endogenous estrogen level. Nucl Med Biol 2007;34:205–10.38. Van Kruchten M., Hospers G.A., Glaudemans A.W. et al. Positron emission tomography imaging of oestrogen receptorexpression in endometrial stromal sarcoma supports oestrogen receptor-targeted therapy: case report and review of the literature. Eur J Cancer 2013;49:3850–5.Van Kruchten M., Hospers G.A., Glaudemans A.W. et al. Positron emission tomography imaging of oestrogen receptorexpression in endometrial stromal sarcoma supports oestrogen receptor-targeted therapy: case report and review of the literature. Eur J Cancer 2013;49:3850–5.39. Yamada Sh., Tsuyoshi H., Tsujikawa T. et al. Predictive value of 16α-[18F]-Fluoro- 17β-Estradiol PET as a biomarker of progestin therapy resistance in patients with atypical endometrial hyperplasia and low-grade endometrial cancer. Clin Nuclear Med 2019;44(7):574–5. DOI: 10.1097/RLU.0000000000002612.Yamada Sh., Tsuyoshi H., Tsujikawa T. et al. Predictive value of 16α-[18F]-Fluoro- 17β-Estradiol PET as a biomarker of progestin therapy resistance in patients with atypical endometrial hyperplasia and low-grade endometrial cancer. Clin Nuclear Med 2019;44(7):574–5. DOI: 10.1097/RLU.0000000000002612.40. Haviland J.S., Owen J.R., Dewar J.A. et al. The UK standardisation of breast radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-years follow-up results of two randomised controlled trials. Lancet Oncol 2013;11:1086–94.Haviland J.S., Owen J.R., Dewar J.A. et al. The UK standardisation of breast radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-years follow-up results of two randomised controlled trials. Lancet Oncol 2013;11:1086–94.41. Choi Y.W., Munden R.F., Erasmus J.J. et al. Effects of radiation therapy on the lung: radiologic appearances and differential diagnosis. Radiographics 2004;24:985–97.Choi Y.W., Munden R.F., Erasmus J.J. et al. Effects of radiation therapy on the lung: radiologic appearances and differential diagnosis. Radiographics 2004;24:985–97.42. Barnett G.C., West C.M., Dunning A.M. et al. Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. Nat Rev Cancer 2009;9:134–42.Barnett G.C., West C.M., Dunning A.M. et al. Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. Nat Rev Cancer 2009;9:134–42.43. Venema C.M., de Vries E.F.J., van der Veen S.J. et al. Enhanced pulmonary uptake on 18F-FES-PET/CT scans after irradiation of the thoracic area: related to fibrosis? EJNMMI Res 2019;9(1):82. DOI: 10.1186/s13550-019-0549-y.Venema C.M., de Vries E.F.J., van der Veen S.J. et al. Enhanced pulmonary uptake on 18F-FES-PET/CT scans after irradiation of the thoracic area: related to fibrosis? EJNMMI Res 2019;9(1):82. DOI: 10.1186/s13550-019-0549-y.44. Douin-Echinard V., Laffont S., Seillet C. et al. Estrogen receptor α, but not β, is required for optimal dendritic cell differentiation and CD40-induced cytokine production. J Immunol 2008;180:3661–9.Douin-Echinard V., Laffont S., Seillet C. et al. Estrogen receptor α, but not β, is required for optimal dendritic cell differentiation and CD40-induced cytokine production. J Immunol 2008;180:3661–9.45. Lammertyn E.J., Vandermeulen E., Bellon H. et al. End-stage cystic fibrosis lung disease is characterised by a diverse inflammatory pattern: an immunohistochemical analysis. Respir Res 2017;18:10.Lammertyn E.J., Vandermeulen E., Bellon H. et al. End-stage cystic fibrosis lung disease is characterised by a diverse inflammatory pattern: an immunohistochemical analysis. Respir Res 2017;18:10.46. Chotirmall S.J., Greene M.C., Oglesby I.K. et al. 17β estradiol inhibits IL-8 in cystic fibrosis by upregulating secretory leucoprotease inhibitor. Am J Respir Crit Care Med 2010;182:62–72.Chotirmall S.J., Greene M.C., Oglesby I.K. et al. 17β estradiol inhibits IL-8 in cystic fibrosis by upregulating secretory leucoprotease inhibitor. Am J Respir Crit Care Med 2010;182:62–72.47. Taniuchi S., Fujishima F., Miki Y. et al. Tissue concentrations of estrogens and aromatase immunolocalization in interstitial pneumonia of human lung. Mol Cell Endocrinol 2014;392:136–43.Taniuchi S., Fujishima F., Miki Y. et al. Tissue concentrations of estrogens and aromatase immunolocalization in interstitial pneumonia of human lung. Mol Cell Endocrinol 2014;392:136–43.48. Cohen Y., Gellei B., Robinson E. Bilateral radiation pneumonitis after unilateral lung and mediastinal irradiation. Radiol Clin Biol 1974;43:465–71.Cohen Y., Gellei B., Robinson E. Bilateral radiation pneumonitis after unilateral lung and mediastinal irradiation. Radiol Clin Biol 1974;43:465–71.49. Van der Veen S.J., Faber H., Ghobadi G. et al. Decreasing irradiated rat lung volume changes dose-limiting toxicity from early to late effects. Int J Radiat Oncol Biol Phys 2016;94:163–71.Van der Veen S.J., Faber H., Ghobadi G. et al. Decreasing irradiated rat lung volume changes dose-limiting toxicity from early to late effects. Int J Radiat Oncol Biol Phys 2016;94:163–71.50. Ghobadi G., Bartelds B., van der Veen S.J. et al. Lung irradiation induces pulmonary vascular remodelling resembling pulmonary arterial hypertension. Thorax 2012;67:334–41.Ghobadi G., Bartelds B., van der Veen S.J. et al. Lung irradiation induces pulmonary vascular remodelling resembling pulmonary arterial hypertension. Thorax 2012;67:334–41.51. Yang Z., Sun Y., Yao Z. et al. Increased [18]F-fluoroestradiol uptake in radiation pneumonia. Ann Nucl Med 2013;27:931–4.Yang Z., Sun Y., Yao Z. et al. Increased [18]F-fluoroestradiol uptake in radiation pneumonia. Ann Nucl Med 2013;27:931–4.